Methodist Le Bonheur Healthcare: First to offer the Eluvia ™ Drug-Eluting Vascular Stent

Posted on: February 27, 2019

ELUVIAClaro Diaz, MD, an interventional cardiologist with Methodist Le Bonheur Healthcare, is the first physician in the greater Memphis area to use the Eluvia Drug-Eluting Stent to treat patients with peripheral arterial disease (PAD). This new stent is the latest advancement to treat blocked arteries in patients with PAD. The first procedure was performed at Methodist North Hospital.

“This new technology is an exciting advancement for patients with PAD,” said Dr. Diaz. “It will help me improve the results I can achieve with my patients.”

When a stent or balloon is used during intervention to open an artery, the artery heals by forming a new lining. In some cases too many cells that form the lining are made, which results in restenosis, or a narrowing of the artery. The Eluvia Drug-Eluting Stent offers an innovative solution to deliver a sustained release of medication over a period of one year to help prevent the artery from re-narrowing. It was recently approved by the FDA.

PAD affects approximately 8.5 million Americans over the age of 40. The most common symptom of PAD is muscle cramping in the hips, thighs or calves while walking, climbing stairs or exercising. Physicians are more likely to see patients who have atypical symptoms including fatigue in the legs, or an ache in the hip or thigh pain. For both men and women the prevalence of the disease increases with age. If plaque buildup is the cause of peripheral arterial disease, patients may be at risk of developing critical limb ischemia, stroke or heart attack. The Eluvia Drug-Eluting Stent is a breakthrough as it helps keep arteries open and blood flowing to vitally important areas of the body.

Physicians can diagnose a narrowing of the peripheral arteries leading to the legs, stomach, arms and head by listening through a stethoscope for bruit, an abnormal sound in blood flow, by examining the nail beds, and by feeling the pulse in the feet and legs.

The ideal candidates to receive the Eluvia Drug-Eluting Stent are diabetics who have high restenosis with medium to long blockages.

To learn more, visit